PTC Therapeutics Management
Management criteria checks 2/4
PTC Therapeutics' CEO is Matt Klein, appointed in Mar 2023, has a tenure of 1.83 years. total yearly compensation is $8.94M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 0.068% of the company’s shares, worth €2.34M. The average tenure of the management team and the board of directors is 5.8 years and 9.6 years respectively.
Key information
Matt Klein
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 8.4% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.07% |
| Management average tenure | 5.8yrs |
| Board average tenure | 9.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$453m |
| Jun 30 2024 | n/a | n/a | -US$480m |
| Mar 31 2024 | n/a | n/a | -US$579m |
| Dec 31 2023 | US$9m | US$747k | -US$627m |
| Sep 30 2023 | n/a | n/a | -US$642m |
| Jun 30 2023 | n/a | n/a | -US$618m |
| Mar 31 2023 | n/a | n/a | -US$571m |
| Dec 31 2022 | US$5m | US$598k | -US$559m |
Compensation vs Market: Matt's total compensation ($USD8.94M) is above average for companies of similar size in the German market ($USD1.88M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt Klein (52 yo)
1.8yrs
Tenure
US$8,937,025
Compensation
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$8.94m | 0.068% € 2.3m | |
| Co-Founder | 27yrs | US$5.66m | no data | |
| Co-Founder | 27yrs | US$511.98k | 0.016% € 549.7k | |
| Chief Financial Officer | 1.5yrs | US$3.01m | 0.015% € 531.2k | |
| Executive VP & Chief Legal Officer | 12.8yrs | US$2.19m | 0.063% € 2.2m | |
| Chief Business Officer | 9.8yrs | US$2.41m | 0.026% € 878.4k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$2.39m | 0.019% € 662.0k | |
| Senior VP | 5.6yrs | US$1.70m | 0.022% € 759.2k | |
| Chief Technical Operations Officer | 6.1yrs | US$2.67m | 0.054% € 1.8m | |
| Senior VP & Chief Information Officer | less than a year | no data | no data | |
| Investor Relations Officer | no data | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data |
5.8yrs
Average Tenure
57yo
Average Age
Experienced Management: BH3's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$8.94m | 0.068% € 2.3m | |
| Co-Founder | 1.8yrs | US$5.66m | no data | |
| Co-Founder | 27yrs | US$511.98k | 0.016% € 549.7k | |
| Independent Chairman of the Board | 23.4yrs | US$816.96k | 1.95% € 66.9m | |
| Independent Director | 19.1yrs | US$438.98k | 0.014% € 467.3k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$441.98k | 0.0093% € 320.7k | |
| Member of Scientific Advisory Board | 21.2yrs | no data | no data | |
| Independent Director | 9.6yrs | US$426.98k | 0.014% € 467.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$421.98k | 0.0076% € 261.3k |
9.6yrs
Average Tenure
64yo
Average Age
Experienced Board: BH3's board of directors are considered experienced (9.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 03:43 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PTC Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Huidong Wang | Barclays |
| Geoffrey Meacham | Barclays |